123 related articles for article (PubMed ID: 16765453)
1. During 3 years treatment of primary progressive multiple sclerosis with glatiramer acetate, specific antibodies switch from IgG1 to IgG4.
Basile E; Gibbs E; Aziz T; Oger J
J Neuroimmunol; 2006 Aug; 177(1-2):161-6. PubMed ID: 16765453
[TBL] [Abstract][Full Text] [Related]
2. Serial combination therapy: is immune modulation in multiple sclerosis enhanced by initial immune suppression?
Bar-Or A; Oger J; Gibbs E; Niino M; Aziz T; Renoux C; Alatab S; Shi FD; Campagnolo D; Jalili F; Rhodes S; Yamashita T; Fan B; Freedman MS; Panitch H; Arnold DL; Vollmer T
Mult Scler; 2009 Aug; 15(8):959-64. PubMed ID: 19667022
[TBL] [Abstract][Full Text] [Related]
3. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial.
Wolinsky JS; Narayana PA; O'Connor P; Coyle PK; Ford C; Johnson K; Miller A; Pardo L; Kadosh S; Ladkani D;
Ann Neurol; 2007 Jan; 61(1):14-24. PubMed ID: 17262850
[TBL] [Abstract][Full Text] [Related]
4. Glatiramer acetate immunization induces specific antibody and cytokine responses in ALS patients.
Mosley RL; Gordon PH; Hasiak CM; Van Wetering FJ; Mitsumoto H; Gendelman HE
Amyotroph Lateral Scler; 2007 Aug; 8(4):235-42. PubMed ID: 17653922
[TBL] [Abstract][Full Text] [Related]
5. Long-term treatment of multiple sclerosis with glatiramer acetate: natural history of the subtypes of anti-glatiramer acetate antibodies and their correlation with clinical efficacy.
Karussis D; Teitelbaum D; Sicsic C; Brenner T;
J Neuroimmunol; 2010 Mar; 220(1-2):125-30. PubMed ID: 20153903
[TBL] [Abstract][Full Text] [Related]
6. Blocking effects of serum reactive antibodies induced by glatiramer acetate treatment in multiple sclerosis.
Salama HH; Hong J; Zang YC; El-Mongui A; Zhang J
Brain; 2003 Dec; 126(Pt 12):2638-47. PubMed ID: 12937077
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal magnetic resonance spectroscopic imaging of primary progressive multiple sclerosis patients treated with glatiramer acetate: multicenter study.
Sajja BR; Narayana PA; Wolinsky JS; Ahn CW;
Mult Scler; 2008 Jan; 14(1):73-80. PubMed ID: 17881390
[TBL] [Abstract][Full Text] [Related]
8. [Long-term effects of glatiramer acetate in multiple sclerosis].
Brochet B
Rev Neurol (Paris); 2008 Nov; 164(11):917-26. PubMed ID: 18790510
[TBL] [Abstract][Full Text] [Related]
9. Glatiramer acetate treatment in PPMS: why males appear to respond favorably.
Wolinsky JS; Shochat T; Weiss S; Ladkani D;
J Neurol Sci; 2009 Nov; 286(1-2):92-8. PubMed ID: 19426995
[TBL] [Abstract][Full Text] [Related]
10. Multiple sclerosis: glatiramer acetate induces anti-inflammatory T cells in the cerebrospinal fluid.
Hestvik AL; Skorstad G; Price DA; Vartdal F; Holmoy T
Mult Scler; 2008 Jul; 14(6):749-58. PubMed ID: 18611988
[TBL] [Abstract][Full Text] [Related]
11. Glatiramer acetate.
Comi G; Moiola L
Neurologia; 2002 May; 17(5):244-58. PubMed ID: 12031214
[TBL] [Abstract][Full Text] [Related]
12. Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-beta 1a, and high doses of immunoglobulins.
Sarchielli P; Zaffaroni M; Floridi A; Greco L; Candeliere A; Mattioni A; Tenaglia S; Di Filippo M; Calabresi P
Mult Scler; 2007 Apr; 13(3):313-31. PubMed ID: 17439900
[TBL] [Abstract][Full Text] [Related]
13. Effect of immunosuppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosis.
Janiec K; Wajgt A; Kondera-Anasz Z
Med Sci Monit; 2001; 7(1):93-8. PubMed ID: 11208501
[TBL] [Abstract][Full Text] [Related]
14. Results of a phase I study in patients suffering from secondary-progressive multiple sclerosis demonstrating the safety of the amino acid copolymer PI-2301 and a possible induction of an anti-inflammatory cytokine response.
Kovalchin J; Krieger J; Genova M; Collins K; Augustyniak M; Masci A; Hittinger T; Kuca B; Edan G; Braudeau C; Rimbert M; Patel U; Mascioli E; Zanelli E
J Neuroimmunol; 2010 Aug; 225(1-2):153-63. PubMed ID: 20466440
[TBL] [Abstract][Full Text] [Related]
15. Immunological assay for assessing the efficacy of glatiramer acetate (Copaxone) in multiple sclerosis. A pilot study.
Farina C; Wagenpfeil S; Hohlfeld R
J Neurol; 2002 Nov; 249(11):1587-92. PubMed ID: 12420101
[TBL] [Abstract][Full Text] [Related]
16. In vivo effects of mitoxantrone on the production of pro- and anti-inflammatory cytokines by peripheral blood mononuclear cells of secondary progressive multiple sclerosis patients.
Angelucci F; Batocchi AP; Caggiula M; Frisullo G; Patanella K; Sancricca C; Nociti V; Tonali PA; Mirabella M
Neuroimmunomodulation; 2006; 13(2):76-81. PubMed ID: 16974110
[TBL] [Abstract][Full Text] [Related]
17. Clinical response to glatiramer acetate correlates with modulation of IFN-gamma and IL-4 expression in multiple sclerosis.
Valenzuela RM; Costello K; Chen M; Said A; Johnson KP; Dhib-Jalbut S
Mult Scler; 2007 Jul; 13(6):754-62. PubMed ID: 17613604
[TBL] [Abstract][Full Text] [Related]
18. Secretion of brain-derived neurotrophic factor by glatiramer acetate-reactive T-helper cell lines: Implications for multiple sclerosis therapy.
Ziemssen T; Kümpfel T; Schneider H; Klinkert WE; Neuhaus O; Hohlfeld R
J Neurol Sci; 2005 Jun; 233(1-2):109-12. PubMed ID: 15869765
[TBL] [Abstract][Full Text] [Related]
19. Glatiramer acetate reduces lymphocyte proliferation and enhances IL-5 and IL-13 production through modulation of monocyte-derived dendritic cells in multiple sclerosis.
Sanna A; Fois ML; Arru G; Huang YM; Link H; Pugliatti M; Rosati G; Sotgiu S
Clin Exp Immunol; 2006 Feb; 143(2):357-62. PubMed ID: 16412061
[TBL] [Abstract][Full Text] [Related]
20. Treatment with glatiramer acetate induces specific IgG4 antibodies in multiple sclerosis patients.
Farina C; Vargas V; Heydari N; Kümpfel T; Meinl E; Hohlfeld R
J Neuroimmunol; 2002 Feb; 123(1-2):188-92. PubMed ID: 11880163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
